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1. Introduction
Comprising nearly 50% of the human body [1] skeletal muscles compose the machinery that
sets the body in movement. When well-trained, muscles have the capability to protect joints
and bones from daily waste and trauma [2]. They hold an intrinsic protective mechanism
against cancer formation and metastasis settling [3] and are at the same time the main energy
reservoir of the body storing more than 80% of our glycogen reserve [4]. Hence, muscle tissue
is associated to several functions and networks with different parts of the body. It is composed
of muscle fibers, the contractile units, which are bound together by connective tissue. Most
importantly, skeletal muscles display an astonishing regenerative capacity [5]. Due to resident
stem cells, one week after severe trauma new myotubes are already being formed, and within
28 days after trauma muscle regeneration is almost complete [6]. These intrinsic features turn
the skeletal muscle into a very interesting topic of study in regenerative medicine. Taking
advantage of the regenerative potential of stem and precursor cells, skeletal muscle is con‐
stantly renewed in response to injury, damage or aging. It is this natural process that research‐
ers are about to harness in order to help patients with many muscle diseases and diseases that
causes weakness or destruction of the muscle - for instance stress urinary incontinence (SUI),
muscular dystrophy. In this chapter, the focus will be on the regeneration of the skeletal muscle
and especially in the case of incontinence. Urinary incontinence is the involuntary loss of urine
and is a major medical problem affecting millions of people worldwide. It impairs the quality
of life of patients and involves high healthcare costs. The main reason provoking SUI is the
damage of the sphincter muscle due to childbirth, surgical treatments (as prostatectomy) or as
an effect of aging. Current treatment encompasses behavioral training, pelvic floor exercising,
drugs, medical devices and surgery. Unfortunately, all these options permit only limited
recovery: short-term relief and are often accompanied with complications. The ultimate goal
will be to prevent disease progression and to restore the tissue and its functions.
© 2013 Azzabi Zouraq et al.; licensee InTech. This is an open access article distributed under the terms of the
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Stem cell therapy as a treatment for skeletal muscle diseases is becoming a reality and it
represents a promising alternative for muscle regeneration and for treating SUI in a more
complete and definitive manner.
In this chapter, the homeostasis and maintenance of skeletal muscle is explained in order to
understand the basis behind muscle regeneration. As different types of stem cells have been
demonstrated to form fibers and to develop into skeletal muscle, cell sources for a muscle cell
therapy is discussed. Some of them have also been applied successfully in preclinical and
clinical studies that are going to be described. Finally, we are going to highlight the parts
important for the translational effort into clinics including biomaterials, cell delivery, imaging,
regulatory affairs, and manufacturing.
2. Muscle homeostasis
2.1. Satellite cells are the secret of skeletal muscle regeneration
The secret of skeletal muscle staggering regenerative capacity is found in the specific compo‐
nents of its cell niche. The muscle tissue is composed of long and slender cells that form muscle
fibers grouped in bundles (Figure 1). Adjacent to these myofibers, a heterogeneous pool of
subsarcolemmal progenitor and stem cells known as muscle satellite cells (SC), respectively
committed to myogenic differentiation or to self-renewal, guarantee a fast and efficient
regenerative process after trauma [7]. These cells, activated by injury [8], work hierarchically
to maintain the in situ pool of cells (Figure 1) and to reconstruct damaged tissue in less than
one month by differentiating into new myotubes.
2.2. Injury and inflammation — The role of inflammation
After trauma an inflammatory infiltrate can be observed when neutrophils, macrophages,
satellite cells and later myoblasts work chronologically together cleaning up damaged fibers
and reconstructing new functional myotubes. Neutrophils are the first cells to arrive at the
site of injury, followed by macrophages three hours after damage [6]. Through the com‐
bined action of free radicals, growth factors and chemotactic factors these inflammatory cells
contribute both to injury and repair [9]. Without the neutrophil-related oxidative and pro‐
teolytic modifications of damaged tissue, phagocytosis of debris would not be possible [10].
Macrophages are the major housecleaners that remove remaining debris of fibers. Further‐
more, macrophages produce proteases to lyse the sarcolemma membrane, which allows acti‐
vation and proliferation of SC [11]. Dismantling of the extracellular matrix is key to SC
activation, and the up-regulation of metalloproteinase is required for muscle regeneration
[12]. Macrophage infiltration is also important for SC activation and proliferation by activat‐
ing NF-κB via TWEAK ligand [13]. Quiescent SCs are still found between the basal mem‐
brane and sarcolemma until the third day after injury. Subsequently, they are slowly
replaced by cells with large nuclei, nucleoli, and cytoplasmatic processes filled with ribonu‐
cleoprotein granules. These myoblasts display an initial exponential growth phase and after
the seventh day they start to form myotubes with centrally placed nuclei and peripheral my‐
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Figure 1. The muscle niche is the secret of skeletal muscle astounding regenerative capacity. Attached to bones,
skeletal muscle are organs composed of skeletal muscle tissue, connective tissue, nerves and blood vessels. Each indi‐
vidual skeletal muscle is composed by hundreds or thousands bundles of muscle fibers that are single cylindrical mus‐
cle cells. (A) The connective tissue surrounding each muscle is called epimysium, and its projections that separe muscle
bundles are called perimysium. (B) The connective tissue between single muscle fibers is called endomysium and serv‐
ers as the muscle satellite cells (SCs) niche. SCs are subsarcolemmal cells that can be activated to regenerate new mus‐
cle fibers. (C) Skeletal Muscle tissue is not only formed by muscle fiber, but also by acellular matrix, cellular
components, blood and lymphatic vessels and nerves. Altogether, these muscle niche components play a distinct role
on muscle regeneration and on muscle progenitor cell regulation.
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ofibrils. On the periphery of these newly formed myotubes a new population of subsarco‐
lemmal quiescent cells replenishes the SC pool [6]. Finally, mature myofiber nuclei do not
display mitotic figures throughout the regeneration process, demonstrating that the dam‐
aged fiber cannot heal itself without the activation of satellite cells.
2.3. The role of the muscle niche in muscle regeneration
Components  of  the  muscle  niche  are  important  for  skeletal  muscle  regeneration  and
satellite cell activation. The basal lamina is the common anatomic site of satellite cells and
also contributes to cell fate. The basal lamina is rich in α7β1 integrin which acts directly
in the anchorage, adhesion and quiescence of satellite cells [14]. These integrin functions
also  comprise  the  migration  and  proliferation  of  developing  myoblasts  [15],  the  forma‐
tion and integrity of neuromuscular junctions [16], as well as the binding of muscle fibers.
Another integrin, VLA-4, is expressed as myotubes form and influences the alignment and
fusion of myoblasts [17].  Finally, the calcium-dependent cell  adhesion protein M-cadher‐
in  is  a  morphoregulatory  molecule  facilitating  myoblast  fusion  and  cell  adhesion  to  its
adjacent myofibers [18, 19].
The surrounding acellular matrix (ACM) contains a number of components that can influence
the behavior and regulate the growth of muscle progenitor cells. The ACM is a source of
hepatocyte [20] and fibroblast [21] growth factors, which act on the activation of satellite cells,
proliferation and inhibition of differentiation. Another factor produced by the ACM is the
endothelial growth factor, which promotes satellite cell activation and cell survival after injury
[22]. Finally, the aged ACM is capable of impairing the regenerative potential of satellite cells
and inducing fibrosis by activating the Wnt signaling pathway [23].
Fibroblasts  are  the  main source  of  collagen in  the  muscular  interstitial  space  [24].  They
continuously promote the formation of the basal lamina during myogenesis [25] and after
muscle injury proliferate hand in hand with Pax7 positive satellite cells, orchestrating the
fine balance between muscle reconstruction and fibrosis formation [26]. These fibroblasts
prevent  premature  activation  and  differentiation  of  muscle  progenitor  cells,  thereby
avoiding depletion of the pool of satellite cells. Accordingly, satellite cells are sufficient to
regulate  the  ingrowth  of  fibroblasts  and  fibrosis  formation  [26].  Fibroblasts  are  also
involved in myosin switch from fetal to adult muscle, specially promoting Myosin Heavy
Chain type 1 expression (slow twitch) in several limb muscles in the fetal mouse and in
the soleus in the adult muscle [27].
Circulating and locally produced soluble factors participate in the signaling pathway that
regulates satellite cell activity. During exercise and stretching muscle fibers liberate hepatocyte
growth factor (HGF) through nitric oxide stimulation and induce activation of satellite cells
[28]. HGF can also activate satellite cells by activating the sphingolipid signaling cascade upon
disruption of the laminin-integrin adhesion in the event of trauma [29]. Furthermore, the
insulin-like growth factor 1 (IGF-1), a potent mitogen produced locally during muscle
hypertrophy and injury, can induce activation, proliferation and differentiation of satellite cells
[8, 30]. In contrast, mysotatin, a growth differentiation factor and member of the TGF-beta
protein family secreted by adult skeletal muscle, is capable of inhibiting activation and self-
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renewal of quiescent cells [31]. Finally, a hormone produced by the thyroid gland and
responsible for inducing hypercalcemia named Calcitonin [32], has been associated with delay
of satellite cell activation [33]. Together all these components and products of the muscle niche
are key regulators of all the development and regeneration processes of skeletal muscle.
2.4. Satellite cells are also required for exercise related muscle turn–over
Exercise is capable of activating muscle gene transcription within seconds and these molecular
responses can last for hours even after exercise cessation [34]. During endurance exercise,
muscle consume large amounts of oxygen to generate energy by breaking down carbohydrates
and posteriorly fat [35]. Muscle fibers are not in a smooth continuous muscle contraction
during exercise, but rather act as a series of small groups of fibers contracting at the same time
[36]. This occurs due to stimulation of neuromuscular junctions of terminal branches of axons
whose cell body is in the anterior horn of the spinal cord. Altogether, these nerve and muscle
components comprise the motor unit [37] and conduce impulses that enable sharp muscle
contraction within milliseconds [38]. A signaling pathway is then activated by rapamycin
kinase (mTOR) leading to hypertrophic changes in muscle mass [39]. The opposing effect is
found during starvation when the AMP-activated protein kinase (AMPK) is switched on to
up-regulate energy-conserving processes and ultimately induce muscle atrophy [39]. How‐
ever, exercise is sufficient to increase the pool of stem cells reversing the effects of atrophy after
prolonged limb immobilization [40].
After a trauma or during exercise nitric oxide is liberated and modulates the activation of
satellite cells [41, 42]. Another evidence of this cell addition during exercise is the decrease of
telomeres length detected in marathon runners, which correlates to their running hours [43].
Endurance exercise has been reported to stimulate the production of free radicals like nitric
oxide [44], which has been shown to again induce activation of satellite cells thereby increasing
muscle turn-over [28]. On the other hand, during muscle atrophy caused by limb immobili‐
zation an apoptotic decrease of myonuclei occurs [45] associated with a decrease in mitotic
activity of satellite cells [46]. These findings underline the involvement of satellite cells in the
regulation of muscle mass during exercise.
2.5. Markers for satellite cells
A transcriptional network controls progression of both embryonic and adult muscle stem
cells  [47].  Quiescent  muscle  embryonic  progenitor  cells  can  be  identified  by  the  co-
expression of  the  paired-domain transcription factors  Pax3 and Pax7 (Figure 2)  and are
maintained as a self-renewing proliferative population [48]. During embryogenesis Pax3 is
required to maintain muscle progenitor cells in the somite and further induce cell migration
to the required site of skeletal myogenesis [49]. Indeed the normal expression of Pax3 seems
to be decisive for the development of normal muscle,  and its mutation promotes malig‐
nant growth and induces tumorigenesis in alveolar rhabdomyosarcoma tumor cells  [50].
However,  its  down-regulation is  necessary for final  cell  commitment to myogenesis and
leads  to  rapid  and  robust  entry  into  the  myogenic  differentiation  program  [49].  The
expression of transcription factor Pax7 is detectable in cells  starting from the embryonic
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muscle progenitor to the quiescent and activated satellite cells (Figure2). Its induction in
muscle-derived  stem  cells  induces  satellite  cell  specification  by  restricting  alternate
developmental programs [51].
Figure 2. Myogenic cell characterization and culture. Myogenic cell lineage can be identified in each differentiation
state and pursue tightly regulated proliferation and differentiation cycles. From the embryonic state until the terminal
differentiation into muscle fibers an intricate network of transcription factors regulates the fate of muscle progenitor
cells. These cells can be isolated from any skeletal muscle tissue, grown in culture and reimplanted into a damaged
muscle to promote muscle regeneration.
Specific molecular markers have been demonstrated to distinguish between activated and
quiescent SC. Quiescent satellite cells express the transcription factor Pax7, after activation in
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co-expression with MyoD [52]. This dual expression is followed by a proliferative phase, down-
regulation of Pax7 and terminal differentiation. If Pax3 and Pax7 down-regulation do not occur
in vitro differentiation is blocked [53, 54]. In this context microRNAs (miRNAs) play a regula‐
tory role conferring robustness to developmental timing by posttranscriptional repression of
genetic programs of progenitor and satellite cells [55]. They allow rapid gene program
transitions from proliferation to differentiation, blocking PAX3 [56] and Pax7 [57] activity in
progenitor and satellite cells.
This interplay during development is required to ignite the commitment of satellite cells to the
myogenic program, to activate the myogenic regulatory factors Myf-5 and MyoD and to
promote terminal muscle differentiation [55] [58] [59], which are decisive to subsequent
myoblast cell cycle progression or exit into differentiation. Through the action of the myogenic
regulatory factors (MRFs), Myf5 and MyoD, the muscle progenitor cells (Pax3+) and quiescent
satellite cells (Pax3+/Pax7+) become muscle lineage committed and activated myoblasts [60].
They express Myf5 and Mrf4 and rapidly give rise to Desmin+ cells, whose differentiation is
regulated by myogenin, MyoD and MRF4 [61]. Completing these regulatory features, MyoD
is also a main player in the intricate epigenetic cascade that controls skeletal myogenesis [62].
3. Muscle regeneration
3.1. Cell sources for skeletal cell therapy
Several types of cell populations have been identified as potentially efficient in muscle
regeneration, especially in cell therapy. They are able to self-renew, proliferate and form
muscle fibers. Among these cells some are muscle derived and some are from other origin.
3.2. Muscle–derived cells
Muscle satellite cells, which are squeezed between the plasma membrane and basement
membrane of muscle fibers, are the natural source of muscle regeneration during homeostasis
or after injury in postnatal stages [63]. They are specifically expressing the paired box tran‐
scription factor pax7 [51] and have been shown to be efficient in the muscle regeneration
process. One study illustrated that as little as seven satellite cells were able to generate more
than 100 muscle fibers in irradiated muscle [64]. Though, satellite cells isolated from different
muscles are not equivalent: they produce muscle fibers with variable contractile abilities
depending on the muscle of origin [65]. This can be explained by the fact that a satellite cell
pool does not seem to consist of a homogeneous population of cells [66-70]. Once activated,
satellite cells are triggered toward proliferation and differentiation by giving rise to muscle
precursor cells that fuse and form skeletal muscle fibers [71]. The two techniques used to isolate
muscle precursor cells are selection of single fibers that are cultured or mechanical processing
of muscle biopsies and enzymatic treatment with a mixture of collagenase and dispase [64,
72-74]. The first method is claimed to be less aggressive and to better preserve the cells.
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Another type of cells is isolated from muscle biopsies through a series of preplating stages.
These cells are also recognized to have a myogenic profile and are capable to fuse and form
skeletal muscles fibers. They are known as muscle-derived stem cells (MDSC) with character‐
istics of non-committed progenitor cells [75, 76] and are most probably originating from blood
vessel walls [77]. Similarly, other cells types isolated from the muscle compartment such as
mesoangioblasts and pericytes are involved in the muscle regeneration but are of non-
myogenic origin. These are vessel-associated progenitors, not expressing myogenic markers
such as Myf5 and MyoD even though they can differentiate to myotubes and fuse to form fibers
[78-80]. More cell types with non-myogenic profile are found in the skeletal muscle and have
recently been demonstrated to form fibers. Hence, skeletal myogenic precursors or muscle
stem cells sorted by FACS are capable to reconstitute fibers in rodent models [72, 81]. The first
type of cells is characterized by expression of β1-integrin (adhesion protein) and CXCR4 (SDF-1
receptor), the second type by α7-integrin (adhesion protein) and CD34 markers. Side popula‐
tions are also isolated from muscle tissues and are expressing specific surface markers [82].
They are distinct from satellite cells and have been used successfully in muscle regeneration
in rodent models [83-87]. Surprisingly, more types of cells of the skeletal muscle tissue can
contribute to muscle regeneration. In fact, recently, a new type of myogenic cells, localized in
the area of the interstitium between muscle fibers, has been characterized and is known as
PW1-interstitial cells (PICs). They are characterized as positive for cell stress mediator PW1
but negative for Pax7; though they possess myogenic profile in vitro and lead to muscle
regeneration in vivo, which includes the generation of satellite cells [88]. Hence, various types
of cells isolated from skeletal tissue either mechanically or by flow cytometry are capable to
regenerate muscle. In addition to the muscle there are more sources of stem/precursor cells
isolated from other compartments.
3.3. Sources outside of the skeletal muscle compartment
Mesenchymal stem cells (MSC) are procured from bone marrow biopsies and are multipotent
stem cells that give rise also to skeletal muscle fibers and participate to restore the satellite cell
niche [89]. These cells are well characterized and involved in many different applications due
to their multipotency as it is the case for adipose-derived stem cells (ADSC). The latter are
easily harvested by liposuction, cultured in vitro and injected to restore muscle in the case of
SUI [90, 91]. Embryonic stem cells, induced pluripotent stem cells and umbilical cord blood
have been demonstrated to be good alternatives for skeletal muscle regeneration [74, 92, 93].
However, precaution should be taken when these types of cells are considered for further
development in clinics, as different types of viruses are used during the process of myogenic
induction. In addition, there are still potential tumorigenicity issues with this sort of cells that
need to be solved before further clinical application.
Hence, the sources of stem/progenitor cells for skeletal muscle regeneration are large. Though,
several important factors need to be considered when choosing the optimal source for treating
patients. Autologous cell therapy avoids immunogenic reaction and therefore complications
after the implantation procedure. Therefore, autologous satellite/muscle precursor cells are
advantageous for muscle regeneration. They are committed to muscle restoration and
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therefore the most convenient cells for applications in cell therapy. Their dedication to one
lineage offers an advantage over other, previously discussed sources, which are multipotent
and hence differentiate also into non-muscular tissue cells. Furthermore, satellite / muscle
precursor cells can be isolated in a simple procedure and are easily expanded in a GMP facility.
They produce enough cells to be injected after 2-3 weeks, which is much faster than the 5 - 6
weeks required for muscle derived stem cells. For allogenic application, mesenchymal and
adipose derived stem cells represent valid alternatives when satellite cells cannot be extracted
from the skeletal muscle.
4. Preclinical and clinical studies
Several animal studies have been addressing the problem of stress urinary incontinence (SUI)
and different strategies have been tested to restore continence, either by applying pharmaco‐
logical therapies, bulking agents, sling surgical procedures or cell-based therapies [94]. Until
now, the first three strategies mentioned above are commonly applied in clinics. However, the
outcomes are associated with adverse events and limited effectiveness in middle and long
terms [95-97]. Therefore, cell-based therapies are aiming to bring new solutions to the treat‐
ment of SUI. Numerous preclinical studies have been implementing stem/progenitor cell
injections for restoration of muscle contraction in SUI. Animal models that mimic SUI are
crucial for the understanding of effects and benefits of the different therapies options.
4.1. Animal model
To stimulate SUI in animals, various methods were applied. The goal is to injure one or
several aspects of the urinary continence mechanisms to provoke incontinence as found in
patients. The methods comprise the compression of the muscular and neurological system
involved in continence by vaginal distension [98,  99],  crush of the pudental nerve [100],
damaging  of  anatomic  supports  such  as  fascia  and  pubourethral  ligament  [101-104]  or
destruction  of  intrinsic  urethra  by  periurethral  cauterization,  urethral  sphincterectomy,
pudendal nerve transection and botulinum toxin periurethral injection [105-112]. One has
to note that vaginal distension or pudendal nerve injury are relatively limited models due
to the fact that the injury is naturally recovered after 2 weeks and thereby does not mimic
an irreversible SUI. Eberli  et al.  have been describing a large animal model for SUI that
was followed for 6 months. In this study, the sphincter muscle of dogs has been irreversi‐
bly  damaged  by  surgically  removing  part  of  it.  During  the  follow-up,  the  dogs  were
permanently  affected  by  this  procedure  with  long  term decrease  in  sphincter  pressures
[107].
4.2. Preclinical studies
Rats are the preferred animal models for studying safety and efficacy of several cell types for
treatment of SUI (table.1).
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Cell type Animalmodel SUI model
Injection
Target organ
Time
point
Weeks
Reference Year
MDSC SCID mice /Rats Cryoinjury bladder Bladder 1 to 4 Huard et al. 2002
MPC Mice Noxetin Urethral 2 to 4 Yiou et al. 2002
MDSC Rats Sciatic nerve section Urethral 4 Lee et al. 2002
MDPC Rats Sciatic nerve section Urethral 2 Cannon et al. 2003
MPC Rats Electrocoagulation Urethral 0.7 to 4 Yiou et al. 2003
MDSC Rats Pudendal nerve section Urethral 12 Lee et al. 2004
MDC Rats Electrocauterization Urethral 2 to 6 Chermanskyet al. 2004
MDSC Rats Sciatic nerve section Urethral sling 2 Cannon et al. 2005
MDC
fibroblasts Rats Sciatic nerve section Urethral 4 Kwon et al. 2006
Myoblasts Rats Cryoinjury / noxecin Urethral 1 to 6 Praud et al. 2007
Myofibers Pigs Urethral injury Myofiberimplantation 4 Lecoeur et al. 2007
MDSC_FACS
sorted Rats
Nerve transection /
sphincter injury Urethral 4 to 12 Hoshi et al. 2008
ADSC Rats Vaginal dilatation Urethral 4 Lin et al. 2010
BMSC Rats Sciatic nerve section Urethral sling 4 to 12 Zou et al. 2010
BMSC Rats urethrolysis / cardiotoxin Urethral 13 Kinebuchi etal. 2010
MDSC Rats Pudendal nerve section Urethral 1 to 4 Xu et al. 2010
Myoblasts /
ADSC Rats Vaginal dilatation Urethral 4 Fu et al. 2010
UCBSC Rats Electrocauterization Urethral 2 to 4 Lim et al. 2010
BMSC Rats Pudendal nerve section Urethral 4 to 8 Corcos et al. 2011
BMSC Rats Pudendal nerve section Urethral 4 Kim et al. 2011
BMSC Rabbits Cryoinjury Urethral 1 to 2 Imamura etal. 2011
ADSC Rats Pudendal nerve section Periurethral 3 to 4 Wu et al. 2011
ADSC Rats Pelvic nerve section Periurethral 2 to 4 Watanabe etal. 2011
ADSC Rats Pudendal nerve section Periurethral 8 Zhao et al. 2011
MPC Dogs Urethral sphincterecomy Periurethral 24 Eberli et al. 2012
BMSC Rats Pudendal, other nervessection
Urethra and
baldder neck 1 to 8 Du et al. 2012
MSC Rats Vaginal dilatation intravenously 0.6 to1.4 Cruz et al. 2012
Abbreviations: ADSC, adipose-derived stem cells; BMSC, bone-marrow mesenchymal stem cells; MDC, muscle-derived
cells; MDSC, muscle-derived stem cells; MPC, muscle precursor cells; MSC, mesenchymal stem cells; UCBSC, umbilical cord
blood stem cells;
Table 1. Animal studies for treating stress urinary incontinence based on cell therapy.
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Muscle derived cells were the first cells to be used for urethral regeneration and to demonstrate
that cell therapy might represent an option for the treatment of SUI. Hence, MDSC, myoblasts,
MPCs or muscle fibers injected around the injured area were surviving, participating in fiber
formation and re-establishing muscle contractility [113-118]. In rat models, it was shown that
the injected MDSC – isolated by preplating procedures or FACS-sorted - were participating
actively in muscle regeneration for up to 3 months [119, 120]. Interestingly, in a dog study, a
rare large animal model for SUI, transplanted MPCs were efficiently restoring the sphincter
pressure to 80% of normal values during a half year follow-up period [121]. Concerning the
speed of regeneration, Cannon et al. noticed 87% recovery after only 2 weeks post-injection
and Chermansky et al. a full recovery after 4 weeks with myoblast and 6 weeks with MDSC
[113, 116, 122]. Hence, muscle derived cells are able to incorporate the urethral structure and
help recovering continence by reconstructing new fibers and connections with the surrounding
cells – nerves, Schwan cells, vessels etc. [119, 121]. However, they are not the only kind of cells
facilitating this cell therapy. Bone marrow derived mesenchymal stem cells, adipose-derived
stem cells, umbilical cord blood stem cells (UCBSC) have been proven to also restore continence
in animal SUI models [123-135]. In fact, different studied showed that these cells are contri‐
buting to the formation of fibers and contractile muscles which permit to control urinary
leakage. When compared to common procedures for treatment of SUI such as the injection of
collagen bulking agent, ADSC cell therapy provided better results [132]. Moreover, the
association of cells with biomaterials seems to enable further improvements as observed with
BMSC and sling systems or MDSC with fibrin glue [135, 136]. To improve this cell therapy
model, Zhao et al. took account of the fact that muscle regeneration is an interaction process
involving paracrine factors produced by surroundings cells and combined with ADSC the
nerve growth factors. This method stimulated muscle regeneration and demonstrated that
combining different cell types could be beneficial for muscle restoration in SUI.
4.3. Clinical trials
Several clinical trials applying cell therapy in SUI have been conducted in the last decade
(table.2).
Safety and efficacy of this strategy have been proven with several types of cells in women and
men. As the procedures differ from one trial to another straight comparisons between them
are difficult. Additionally, the recruited patients suffered from different levels of SUI - from
moderate to severe- and some studies even included complementary therapies such as
electrical stimulation or exercises to improve the results. Nevertheless, the results were highly
promising and have demonstrated that a solution for patients suffering of SUI is within reach.
Surprisingly, the first cells to be used in a clinical trial for SUI was not muscle derived cells but
chondrocytes isolated from auricular cartilage that were expanded in culture before injection
in female patients. Out of 32 treated patients 26 had an improved situation and 50% were
continent after one year [137]. This was the only clinical study using chondrocytes for voiding
dysfunction. Muscle derived cells (myoblasts and MDSC) are the most frequently used cells
in muscle regeneration for SUI in both genders. Myoblasts have been used in many trials and
were injected in or around the external urethral sphincter. The efficiency was stated to be
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between 50% and 88% in a follow-up of 12 months [138-141]. Even if the designs between
studies differ, the combination of cell therapy with electrical stimulation or/and pelvic floor
exercises may explain the variation between the values. In fact, a cell therapy with the
application of myoblasts alone seems to provide a 50% improvement [139, 141], improving to
78.4% if electrical stimulation is added [138] and reaching 88% with pelvic floor exercises [140].
This approximate comparison can encourage future clinical studies to combine other therapies
and exercises with cell therapies in order to optimize the outcome. Myoblasts have also been
combined with fibroblasts mixed in a collagen solution. The results were impressive: 79% of
treated women and 65% of the men reached continence [142, 143]. As a Lancet publication of
this group was retracted, these results should be handled with precaution and should be
confirmed by other groups [144]. Other muscle-derived cells have been injected in patients
with SUI. Since 2008, MDSC have been applied in several clinical trials [145, 146] with
improvement rates of 53% after 1-year follow-up with 10 million cells injected, 63% with 20
million and 67% with 50 million. The efficiency of the cell therapies seems to be dose-depend‐
ent. This was confirmed by Kaufman et al. in a 6-month dose escalating study, where im‐
provements increased with the dose of injected cells. The best results were obtained with 200
million MDSC injected [146]. Interestingly, no serious adverse effects were observed even
when numbers of UCBSC as high as 400 million were applied [147]. In this latter case, 72% of
Cell type Source Patients / n Injection Target organ Deliverybiomaterial
Time point
Months
Outcomes
Measurements Reference Year
Chrondrocytes autologous Women / 32 Trans/peri-urethral Bladder neck calcium alginate 12
81% improved
50% continent Bent et al. 2001
Myoblasts and
fibroblasts autologous Woman / 123 Transurethral Urethra
autologous serum
collagen 12
79% continent
13% improved
Mitterberger
et al. 2007
Myoblasts and
fibroblasts autologous men / 63 Transurethral Urethra
autologous serum
collagen 12
65% continent
17% improved
Mitterberger
et al. 2008
MDSC autologous Women / 8 Trans/peri-urethral
External
sphincter none 3 to 24
63% improved
13% continent Carr et al. 2008
Myoblasts autologous Boys / 7Girls / 1 Transurethral
External
sphincter
none
autologous serum 12 to 18
88% improved
38% continent
Kajbafzadeh
et al. 2008
UCBSC allogenic Women / 39 Transurethral Submucosa none 12 72% improved9% continent Lee et al. 2010
Myoblasts autologous Women / 12 Transurethral Externalsphincter none 12
50% improved
25% continent Sèbe et al. 2011
MDC autologous Men / 222 Transurethral Externalsphincter none at least 12
12% continent
42% improved
46% no efficacy
Gerullis et al. 2012
ADSC autologous Men / 3 Transurethral
External
Urethra
sphincter
Submucosa
space
none 6 improvement Yamamotoet al. 2012
Myoblasts autologous Women / 38 Intrasphincteric
External
Urethra
sphincter
none 1.5
78.4% improved
13.5% cured
8.1% unchanged
Blagange et al. 2012
Abbreviations: MDC, muscle-derived cells; MDSC, muscle-derived stem cells; UCBSC, umbilical cord blood stem cells.
Table 2. Clinical trials for treating stress urinary incontinence based on cell therapy.
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39 patients were more than 50% satisfied 12 months post-injection. This represents another
type of cells that is suitable for SUI treatment. Although the cell therapy with UCBSC is
allogenic, no immunosuppressive effects were observed during this cure. As a source of
multipotent stem cells, ADSC were trusted in recovering the contractility of the sphincter
muscle in patients [148]. Certainly, the encouraging preclinical studies enabled transplantation
of ADSC in patients suffering from SUI. However, only 3 patients were treated so far. Peri‐
urethral injection of ADSC seems to be safe and showed improvement of the sphincter
contraction after 6 months follow-up. The use of total nucleated cells associates with lysates
seems to be another good option for treating SUI. This type of cells significantly helped all
treated patients in the study: 100% noticed improvement in their situation and 88% reached
complete continence after 6 months. Hence, these clinical trials show that different sources of
cells were able to improve the continence level of patients suffering from SUI.
5. Non–biological translational work
The ability to regenerate muscle tissue from patient derived cells would have profound impact
on many human diseases. Cell therapy is within reach as a novel treatment option for incon‐
tinence, reflux, vocal cord dysfunction and other muscle-related pathologies. However, the
carrier used for cell delivery and the techniques used to inject the cells are still being optimized.
5.1. Cell delivery
It has been demonstrated for more than a decade that cells injected in a saline solution carrier
are able to ectopically form contractile muscle [149]. However, further studies have reported
very poor cell survival rates (5-20%) associated with myogenic cell implantation without
embedding into protein based carriers that support cell settling into their new niche [150, 151].
Species-specific cues play an important role in cell affinity to carriers. A previous study
demonstrated advantages using collagen rather than matrigel coated dishes, boosting cell
growth and differentiation potential [73]. In contrast, another study with porcine satellite cells
demonstrated cell preference to matrigel coated dishes and growth decrease on collagen
layers[152]. Moreover, three-dimensional (3D) matrigel coated PLGA (poly lactic-co-glycolic
acid) scaffolds were capable of improving cell survival when compared to direct cell injection
[153]. However, the same study failed to demonstrate a comparative improvement of matrigel
coated PLGA with other cell carriers. Furthermore, matrigel has not presented advantage in
vivo as a carrier for myogenic cells when compared to hyaluronic acid-photoinitiator (HA-PI)
complex. It rather downgraded the quality of muscle structure and decreased the total number
of new myofibers after cell injection [154].
Collagen is a main component of the natural extracellular matrix of skeletal muscle, it is
therefore expected that satellite cells would have their functionality up-scaled in a collagen
rich environment [155]. Combined with electrical stimulation collagen induces three-dimen‐
sional expansion of muscle precursor cells in vitro and in syngeneic recipient muscle [156]. Cell
cycle analyses of engrafts implanted into a 3D collagen sponge highlighted the increment of
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cell fractions in proliferating phases, with 80% of cell survival [157]. In addition, the use of
parallel aligned collagen nanofibers yielded good proliferation and enabled the generation of
aligned cell layers [158]. Finally, grafts of myoblasts seeded into three-dimensional collagen
scaffolds and implanted into injured sites in mice demonstrated improvement in muscle
healing, innervation and vascularization [159]. Altogether these recent studies confirm that
collagen is a very promising matrix for satellite cell ingrowth and an ideal carrier for the
transplantation of myogenic cells.
5.2. Imaging techniques for guided cell implantation in vivo
The success of cell transplantation into a specific site in vivo is directly dependent of 3 key
points: cell source, cell carrier and injection technique. The first two were previously discussed
in this chapter. We dedicate this section to the discussion of injection techniques used so far
to inject myogenic cells into a specific injury site. The application of myogenic cells was already
used for the treatment of male and female patients suffering from urinary incontinence, the
involuntary loss of urine that represents a hygienic and social problem [160]. Transurethral
ultrasound guided injections of autologous cells isolated from limb skeletal muscle biopsies
were so far the method of choice [161, 162]. This method is also standard for the injection of
bulking agents like collagen in the clinical practice [163]. Finally, ultrasound guidance was also
used to monitor percutaneous trans-coronary-venous transplantation of autologous myoblasts
in infarcted myocardium [164, 165].
Recently magnetic resonance imaging (MRI) has gained attention as a useful tool for guidance
during injection of drugs and potentially of cells [166]. Pulsed focused ultrasound is a new
ultrasound technique that associated with magnetic resonance guidance was recently sug‐
gested as a new imaging modality that may be utilized to target cellular therapies by increasing
homing to areas of pathology [167]. It has also been demonstrated to increase drug uptake into
a specific target in the prostate [168] and brain [169]. This same technique has been shown to
facilitate the delivery of neural stem cells into a specific site in the brain [170]. Overall, the most
successful deliveries of myogenic cells have been done either operatively in 3D scaffolds or in
collagen carrier that facilitates cell settling into the new cell niche. Ultrasonography is still the
most adaptable and widely used imaging technique allowing visualization of the injury zone
and real time needle guidance. However, new approaches combining MRI and ultrasono‐
graphic pulses are very promising methods that need to be further studied and adapted for
cell injection in different anatomic sites. Moreover, MRI is used in tracking stem cells after
injection [171, 172]. In fact, it is important not only to inject the cells at the right place but also
to ensure that cells are not migrating to other parts and pursuing their role in regenerating the
tissue of interest. Additionally, developments in MRI technology, especially in scanning
technics, offer the possibility to follow the differentiation process of injected MPCs and their
fate in making fibers [173].
5.3. Regulation and guidelines
The application of cell-based therapies is not only advancing scientifically but also regulations
are adapting and including the new scientific discoveries for clinical use. The relevant health
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agencies all around the world are creating committees that are modifying the regulations in
order to take account of these new categories of products that are cell-based. Stem cell based
therapies are part of advanced therapies, which are therapies based on genes, or cells, or tissues
[174]. Concerning this emerging branch of medicinal products, the regulations are new and
still in development. They have their own classification, distinct from chemical and biologic
drugs, transplantation organs and medical devices. Though, they can be sometimes included
in these categories. In Europe, the European Medicines Agency (EMA) is in charge of improv‐
ing the standards and reviewing the applications for stem cell based therapies, which are part
of Advanced Therapy Medicinal Products (ATMP), and they are found in regulation (EC) N°
1394/2007 [175]. The Committee for Advances Therapies (CAT) is the body responsible within
EMA of this new field of science and its approval for marketing. The goals are to protect the
patient from contaminated tissues/cells, to avoid the inappropriate handling of tissues/cells
and to guaranty safety and efficacy of therapies. The documents are providing a regulatory
framework that is coherent with existing ones, specific to biological and chemical entities for
instance. Hence, before starting any clinical trial on human, several requirements are to be
fulfilled. The cell-based product needs to be grounded on a sound and solid scientific work
that is confirmed in pre-clinical studies, which show its quality, safety and efficacy. During
this preparation phase, CAT is available for giving advice in preparing all the relevant files for
obtaining clinical trials authorization or latter for marketing authorization. Guidelines are
specifying aspects of pharmacovigilance, risk management planning, monitoring, labeling,
safety, efficacy follow-up and traceability. The submission process should comply with these
requirements in order to receive the green light for starting clinical trials or entering the market.
During product development and clinical investigations guidelines have also been adapted
by CAT for stem-cell based therapies for specifications on Good Manufacturing Practice (GMP)
and Good Clinical Practice (GLP) [176]. In the US, the Office of Cellular, Tissue, and Gene
Therapies (OCTGT) - part of the Center for Biologics Evaluation and Research (CBER) in FDA-
is responsible of the cellular therapies products [177]. They are regulated by human cells,
tissues, and cellular and tissue-based products (HCT/Ps) under the authority of Section 361 of
the Public Health Services (PHS) Act as well as Title 21 of the Code of Federal Regulations
(CFR) part 1271 [178]. The OCTGT are making sure that the cell-based products meet safety,
purity, potency and effectiveness qualifications. EMA and FDA are collaborating closely
together in the Advanced Therapies Medicinal Product cluster. The development of regulatory
frameworks is not equal in all countries and is independent from a state to another state.
However, at the international level, regulatory agencies are working together in sharing and
harmonizing the regulatory frameworks for cellular therapy products through the Interna‐
tional Conference of Harmonization of Technical Requirements for Registration of Pharma‐
ceuticals for Human use (ICH), the Pan-American health Organization (PAHO), WHO and
Asia-Pacific Economic Cooperation (APEC). This global interaction facilitates the development
of the cellular therapy field and prepares in bringing the products to the markets. As the
experience is right now limited in this field, this discussion panels permits to cover the different
applications and cases among the countries and therefore increase the knowledge levels among
the participants and the regulatory boards. In addition, it creates convergence in the develop‐
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ment of the regulations and guidelines concerning different aspects: manufacturing, quality
assurance, quality control and pre-clinical studies [179].
Therefore, the regulations and guidelines have been reviewed and adapted for some of them
in order to be applied in the field of cell therapy. This paves the road for regenerating the
sphincter muscle by using stem cells.
5.4. Production of cell–therapies
Besides, chemical drugs, medical devices and biotechnology drugs, advanced therapies are
developed and offer tailored solutions for patients. These therapies are based on genes, cells
or tissues.
Cell therapy for skeletal muscle is one of many therapies that are in translational phase and
can be applied in near future on treating patients. As it is involving individuals’ health and
the cell product is delivered to human, safety concerns are raised. In fact, cell therapy product
– as an investigational or marketed one- needs to meet requirements as any medicinal product
or medical device. The goal is to deliver a consistent, safe, good quality and well-defined
product. Therefore, Good Manufacturing Practice (GMP) is requested for the development of
cell-based product, or its production for the market, and it consists on guidelines and regula‐
tions that advertise quality principles for manufacturing biological products. These rules are
covering all the processes from the biopsy up to the final product. It involves several aspects:
Quality management, buildings and facilities, the equipment, the personnel, the documenta‐
tion, the materials management, the processes in production, the monitoring, the packaging
and labeling, the storage and distribution, the laboratory controls.
Advanced therapies are new technology. Hence, protocols, guidelines and regulations that are
used for existing medicinal product cannot be transposed literally for cell therapies and need
adaptations. However, the goals stay the same: safety, quality and efficacy.
5.5. Manufacturing process
In cell therapy, the starting material represents a critical part that takes account of donor
eligibility criteria including age, tissue quality, source accessibility and viral testing. For
skeletal muscle cell therapy, as described above, the sources are multiple and the efficiency of
most of them is good in regenerating muscle in the case of SUI.
As soon as the biopsy is received in the manufacturing site, the GMP requirements have to be
followed. Hence, quality management should be applied at all production steps: processing,
testing, release, storage and transport.
Manufacturing cell product necessities safe and certified raw materials and components for
cell culture and preparation. In addition, upon reception to the GMP facility, the materials
need to be tested in-house regarding quality and safety. Only then, the products can be released
and accepted into the production area by the responsible for quality in the facility. It is highly
recommended by the regulations to use supplements – as cytokines and growth factors- from
human origin and therefore some adaptations are needed in the production protocols coming
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from the research laboratories. One of the major problems in the cell culture is to replace the
fetal bovine serum (FBS). Most of the protocols are still based on this animal derived product.
Recently, some efforts have been made to work with xeno-free medium by replacing FBS with
human serum and platelet lysate [180]. In the case of MPCs, one of the major sources of cells
for muscle cell therapy as described above, pooled human platelet lysate was demonstrated
to be a good alternative to FBS [181]. Other factors are important and must be controlled as
cell seeding, growth rate, differentiation process, markers expression, potency of the cells in
making contractile fibers. The protocols for each step - from receiving the biopsy up to the final
product -must be standardized and approved by local authorities before starting clinical trials.
Standardization means that clear and details protocols should be written and followed without
deviation or modifications. Quality controls are done not only for starting materials but also
at critical steps in production. Quality is a key parameter that applies to all levels of the cell
therapy production: building and facilities environments, equipment, production, labeling,
storage and distribution. The quality unit performs all the controls to show the purity of the
products, the cleanness of the environment, the maintenance of the equipment and the respect
of the specifications set for obtaining a safe, effective and potent cell product. In muscle cell
therapy, the cell population should have a pure or a very high percentage of cells expressing
markers of skeletal cell as described above.
All the stages and elements related to the GMP facility or the production process should be
documents to insure traceability of every single action. The documents should be prepared,
reviewed, approved and distributed as specified in established and written procedures. All
these demanding steps require qualified personnel, well-trained in working in GMP facilities.
It includes good sanitation and health habits and the right skills to accomplish the work with
products for cell therapy. Finally, internal and external audits are conducted regularly to verify
the respect of the GMP regulations and guidelines as validated by the GMP facility and the
authorities.
6. Outlook: Concerns and improvements
6.1. Effects of age
A  decline  of  approximate  30%  in  muscle  strength  and  40%  in  muscle  volume  occurs
between the second and seventh decades of life [182]. Also the total number of MPCs and
their proliferation potential in culture gradually decrease in an age-dependent manner [183]
due to apoptosis [184]. Additionally cell fate is tightly defined by the interactions with the
microenvironment  and the  host  age  is  of  key  importance,  as  the  stem cell  regenerative
capacity reduces in aged niches [185]. We have reported that although human MPCs can
be successfully isolated and grown from patients of all ages and genders (figure 3), both
elderly  and  male  donors  provide  unstable  and  slower  growing  cells  in  vitro  with  de‐
creased contractile output in vivo [186]. Hence, a combination of stem cell and gene therapy
might be needed in older patients [187, 188].
Skeletal Muscle Regeneration for Clinical Application
http://dx.doi.org/10.5772/55739
695
Figure 3. Muscle progenitor cells identification in vitro and muscle formation after transplantation in vivo.
Myogenic cells isolated from the Rectus abdominis of patients undergoing abdominal surgery, grown in culture and
characterized by FACS, immunohistochemistry in vitro. Tissue formation was evaluated in vivo by Hematoxilin and Eo‐
sin staining and immunohistochemistry. Function was assessed by electromyography. A: FACS analyses of cells in P2
expressing Pax 7, MyOD, desmin and upon differentiation induction Myosin Heavy Chain (MyHC). An IgG Isotype con‐
trol (red curve) was used to determine the background, whereas positive cells are plotted as a green curve. Immunocy‐
tochemistry of cells in culture expressing, MyOD (B), MyHC (C), desmin (D), sarcomeric α-actinin (E) (green -Phalloidin
488, blue – DAPI, red - mM anti-IgG Cy3). Muscle cells injected subcutaneously in nude-mice revealed muscle forma‐
tion in vivo (F, G, H) and contraction upon eletrical stimulation (I). HE stained (G) and labelled with sarcomeric α-acti‐
nin-Cy3 and PKH67 (H). Muscle function significantly improved over time (I), with contraction strength still increasing
after 4 weeks.*p=0.015
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6.2. Overcoming pitfalls by reactivating muscle metabolism, tissue vascularization and
innervation
In the context of muscle reconstruction, gene therapy is not aimed at rectifying a genetic
mutation, but at boosting the myogenic potential and ultimately the muscle functionality of
the injected autologous muscle cells. Two key factors have been demonstrated to improve the
quality of satellite cells for transplantation: a better vascularization [189] and endurance
exercise [190]. We have previously described that an angiogenic modification of muscle
precursors can overcame some of the limitations of aged muscle cells [189]. For future
application expanding the knowledge produced on this study and therapeutically combining
it with the intrinsic adaptation effects of endurance exercise would be of major interest. In this
context, studies using muscle-specific PGC-1α transgenic animals demonstrated that ectopic
expression of PGC-1α in muscle seems sufficient to evoke a trained phenotype avoiding muscle
atrophy [191]. Upon activation, PGC-1α in turn controls many, if not all of the adaptations of
skeletal muscle to endurance exercise [192]. Hereafter, PGC-1α muscle-specific transgenic
animals exhibit high endurance, oxidative muscle fibers, an increase in mitochondrial biogen‐
esis and oxidative metabolism, augmented muscle capillarization and a remodeling of the
neuromuscular junction [193, 194].
Although innervation of the newly implanted tissue is also essential to engineer a functional
muscle tissue there is few approaches that could effectively promote nerve ingrowth after
transplantation. Some studies described a spontaneous nerve ingrowth from the neighbor
tissues into the newly transplanted sites [195, 196], but non-invasive methods to induce nerve
ingrowth after newly formed muscle engrafts are still to be investigated. We have recently
proposed that magnetic stimulation supports regeneration of injured muscle with activating
resident stem cells or supporting integration of newly implanted myoblasts [197, 198].
Exposition of injured limb and co-cultures of muscle cells and neurons to magnetic fields was
sufficient to trigger synapses, induce acetylcholine receptors clustering and cause typical
muscular metabolic adaptations verified during endurance exercise [197]. Notwithstanding,
magnetic stimulation mimicked the effects of exercise inducing PGC-1α up-regulation,
induces myogenic cells differentiation and increases nerve fibers and acetylcholine receptor
clustering after cell transplantation [198]. New efforts in establishing functional innervation,
proper vascular network and the development of a high endurance resistance muscle are going
to be the three main pillars supporting future translational studies and bringing myogenic cell
transplantation from bench to bedside.
7. Conclusion
Regeneration of skeletal muscle for SUI is becoming a reality and the cell therapy may soon
be available to patients. Tremendous progresses have been made to understand the science
behind the natural process of skeletal muscle regeneration that involves primarily satellite cells
and their progenitors, MPCs. In addition, these cells are now well-characterized with several
markers at different stages of proliferation and differentiation. They are also interacting
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actively with their environment, which is composed of different types of cells. These neigh‐
boring cells have a significant influence on the environment and on stimulating the factors that
trigger satellite cells renewal, proliferation and differentiation into myofibers. The process is
complicated and involves cocktails of factors and cells. However, the interaction between these
parameters is better-understood and applied in research and preclinical studies to ameliorate
lack of early vascularization and innervation. In clinical trials, the first results are promising
and many patients with SUI were treated successfully. The cell sources are important for a
successful skeletal muscle cell therapy but they must be accompanied by a set of tools to ensure
the safety and the quality of the process: culture medium, biomaterials, imaging for injection
and follow-up. The advances have been made and the solutions are ready, even at the
regulatory level. Although, there is not yet a standardized cell therapy for SUI, the solutions
and the first results are encouraging. The cell therapy for SUI treatment will be certainly part
of the choices that urologists will adopt very soon in hospitals.
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